| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
45,766,000 |
| Market
Cap: |
1.02(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$6.29 - $33.79 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 8 |
| Insider 6 Months : 8 |
| Insider 3/6 Months : 16.5 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Silk Road Medical is a medical device company focused on reducing the risk of stroke and its devastating impact. Co.'s product portfolio are: ENROUTE Transcarotid Neuroprotection System, which is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, which is a self-expanding, self-tapering stent that conforms to patient; ENHANCE Transcarotid Peripheral Access Kit, which is used in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire, which is used for navigating and crossing the target lesion for delivery of interventional devices.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
11,700 |
11,700 |
11,700 |
11,700 |
| Total Buy Value |
$198,783 |
$198,783 |
$198,783 |
$198,783 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
27,257 |
27,257 |
40,770 |
602,067 |
| Total Sell Value |
$483,218 |
$483,218 |
$770,629 |
$28,445,866 |
| Total People Sold |
5 |
5 |
6 |
8 |
| Total Sell Transactions |
6 |
6 |
13 |
58 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Buchanan Lucas W. |
COO/CFO |
• – – |
2020-12-29 |
4 |
OE |
$1.60 |
$60,100 |
D/D |
18,000 |
154,606 |
|
- |
|
| Buchanan Lucas W. |
COO/CFO |
• – – |
2020-12-29 |
4 |
AS |
$60.04 |
$600,364 |
D/D |
(10,000) |
146,606 |
|
-20% |
|
| Buchanan Lucas W. |
COO/CFO |
• – – |
2020-12-14 |
4 |
OE |
$1.60 |
$11,200 |
D/D |
7,000 |
146,606 |
|
- |
|
| Buchanan Lucas W. |
COO/CFO |
• – – |
2020-12-11 |
4 |
OE |
$1.60 |
$11,200 |
D/D |
7,000 |
139,606 |
|
- |
|
| Rogers Erica J. |
President and CEO |
• • – |
2020-12-11 |
4 |
AS |
$58.35 |
$641,867 |
D/D |
(11,000) |
111,608 |
|
2% |
|
| Rogers Erica J. |
President and CEO |
• • – |
2020-12-11 |
4 |
OE |
$1.46 |
$16,400 |
D/D |
11,000 |
114,036 |
|
- |
|
| Davis Andrew S. |
Chief Commercial Officer |
• – – |
2020-12-01 |
4 |
AS |
$56.63 |
$423,112 |
D/D |
(7,472) |
19,802 |
|
-10% |
|
| Davis Andrew S. |
Chief Commercial Officer |
• – – |
2020-12-01 |
4 |
OE |
$1.46 |
$10,909 |
D/D |
7,472 |
27,274 |
|
- |
|
| Buchanan Lucas W. |
COO/CFO |
• – – |
2020-11-25 |
4 |
AS |
$57.08 |
$570,826 |
D/D |
(10,000) |
132,523 |
|
-11% |
|
| Buchanan Lucas W. |
COO/CFO |
• – – |
2020-11-25 |
4 |
OE |
$4.73 |
$47,300 |
D/D |
10,000 |
142,523 |
|
- |
|
| Ruedy Richard |
EVPClin&Reg.Affairs&QA |
• – – |
2020-11-23 |
4 |
OE |
$1.46 |
$171,478 |
D/D |
108,974 |
128,118 |
|
- |
|
| Buchanan Lucas W. |
COO/CFO |
• – – |
2020-11-20 |
4 |
A |
$33.06 |
$2,744 |
D/D |
83 |
132,606 |
|
- |
|
| Ruedy Richard |
EVPClin&Reg.Affairs&QA |
• – – |
2020-11-17 |
4 |
AS |
$59.84 |
$850,972 |
D/D |
(14,221) |
19,144 |
|
-20% |
|
| Ruedy Richard |
EVPClin&Reg.Affairs&QA |
• – – |
2020-11-17 |
4 |
OE |
$1.38 |
$20,218 |
D/D |
14,221 |
26,551 |
|
- |
|
| Rogers Erica J. |
President and CEO |
• • – |
2020-11-11 |
4 |
AS |
$63.44 |
$697,820 |
D/D |
(11,000) |
111,608 |
|
-21% |
|
| Rogers Erica J. |
President and CEO |
• • – |
2020-11-11 |
4 |
OE |
$1.46 |
$16,060 |
D/D |
11,000 |
122,608 |
|
- |
|
| Buchanan Lucas W. |
COO/CFO |
• – – |
2020-11-06 |
4 |
A |
$0.00 |
$0 |
D/D |
21,496 |
132,523 |
|
- |
|
| Davis Andrew S. |
Chief Commercial Officer |
• – – |
2020-11-02 |
4 |
AS |
$61.37 |
$407,484 |
D/D |
(6,640) |
19,802 |
|
-15% |
|
| Davis Andrew S. |
Chief Commercial Officer |
• – – |
2020-11-02 |
4 |
OE |
$1.46 |
$9,694 |
D/D |
6,640 |
26,442 |
|
- |
|
| Buchanan Lucas W. |
COO/CFO |
• – – |
2020-10-14 |
4 |
AS |
$65.21 |
$626,020 |
D/D |
(9,600) |
111,027 |
|
-17% |
|
| Buchanan Lucas W. |
COO/CFO |
• – – |
2020-10-14 |
4 |
OE |
$4.73 |
$45,408 |
D/D |
9,600 |
117,898 |
|
- |
|
| Rogers Erica J. |
President and CEO |
• • – |
2020-10-12 |
4 |
AS |
$66.16 |
$1,326,133 |
D/D |
(20,044) |
111,608 |
|
-18% |
|
| Rogers Erica J. |
President and CEO |
• • – |
2020-10-12 |
4 |
OE |
$1.46 |
$29,264 |
D/D |
20,044 |
131,652 |
|
- |
|
| Davis Andrew S. |
Chief Commercial Officer |
• – – |
2020-10-01 |
4 |
AS |
$65.60 |
$435,239 |
D/D |
(6,635) |
19,802 |
|
-7% |
|
| Davis Andrew S. |
Chief Commercial Officer |
• – – |
2020-10-01 |
4 |
OE |
$1.46 |
$9,687 |
D/D |
6,635 |
26,437 |
|
- |
|
410 Records found
|
|
Page 11 of 17 |
|
|
0.27 (1.2%) 
